[ET Net News Agency, 5 October 2021] Akeso, Inc. (09926) said the PD-1/VEGF bispecific
antibody (research and development code: AK112), the novel immuno-oncology drug
independently developed by the company, obtained clinical trial approval from the Center
for Drug Evaluation (CDE) of the National Medical Products Administration of the People's
Republic of China to initiate clinical trial for the treatment of advanced triple-negative
breast cancer.
This is a multi-centre, open, randomised phase II clinical trial to evaluate the safety
and efficacy of AK112 in combination with chemotherapy for the treatment of patients with
advanced triple-negative breast cancer. (RC)